Diversity and Equity Are Critical to the Work We Do

Systemic racism is as real as any disease.

The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.

Our Continued Commitment to Industry Change

Health Equity

We’re working with patients, community groups and policymakers to address
social determinants of health and to drive proactive research that expands
data collection and improves health outcomes.

clinical trial diversity

Clinical Trial Diversity

Desktop CTA: (shows in EE only)

We’re committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.

Mobile CTA: (shows in EE only)


We aim to grow the talent pool, create new pathways to our industry and foster more inclusive work environments so that our workforce better reflects census representation top to bottom and side to side.

Voices from Our Blog

Systemic racism is as real as any disease and our industry is not immune
By Courtney Christian
A photograph of Courtney Christian, a Senior Director of Policy and Research at PhRMA
A photograph of Courtney Christian, a Senior Director of Policy and Research at PhRMA
Systemic racism is as real as any disease and our industry is not immune
By Courtney Christian

PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in DC-based, Black-owned newspapers the Informer and the AfroAmerican. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…

A collage image showing screenshots from a video call between Stephen Ubl and Vas Narasimhan
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
By Stephen J. Ubl
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and...
Emily Donaldson
Addressing data challenges to improve health equity
By Emily Donaldson
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to tackling these issues head-on and addressing health disparities that disproportionately affect communities of color and other underserved communities.
PhRMA will continue to advocate for equity within our industry
By Yolanda Hutchins

When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…

Three ways the pharmaceutical industry can positively impact health equity
By Dr. Charlotte Jones-Burton

“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.

I urge you to follow the progress at PhRMA.org/Equity.”

A Message from PhRMA President and CEO Stephen J. Ubl